Abstract Library

#4105 Long-term outcomes for medically managed carcinoid heart disease patients: A retrospective, longitudinal survey

Introduction: Carcinoid Heart Disease (CHD) is a component of carcinoid syndrome. Patients with mild to moderate CHD and no indication for surgical intervention receive medical management (MMCHD).

Conference:

Presenting Author:

Authors: Fisher J, Montague K, Adigun R, Hayes A, Furtado-O'Mahony L,

Keywords: carcinoid syndrome, carcinoid heart disease, survival, medical management,

#2833 Surgical Correction of Carcinoid Heart Disease Improves Liver Function and 5-Hydroxyindoleacetic Acid Levels

Introduction: Neuroendocrine tumours of the gastrointestinal tract cause carcinoid syndrome and carcinoid heart disease. These tumours secrete serotonin, which can bind to heart valves and cause fibrosis and valve incompetence. Most cases involve the tricuspid valve +/- pulmonary valve. Medical management comprises diuretics for fluid overload and somatostatin analogues to reduce circulating serotonin. Definitive treatment is heart-valve replacement surgery which improves exercise tolerance but has high perioperative mortality. We have previously reported that valve-replacement surgery can reduce 5-hydroxyindoleacetic acid (5-HIAA) levels, reflecting a decline in hormone activity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Shah H

Authors: Shah H, Sagar V, Venkataraman H, Steeds R, Rooney S,

Keywords: carcinoid, carcinoid syndrome, neuroendocrine tumour, carcinoid heart disease, 5hiaa,

#2163 Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Carcinomas: Case Series

Introduction: High-grade neuroendocrine carcinomas (NECs) possess inevitable tendencies to metastasise and hold poor prospects of survival. Patients with neuroendocrine tumours who progress after medical management can be treated with peptide receptor radionuclide therapy (PRRT), on the proviso that there is positive uptake on 68Ga-DOTATATE PET/CT imaging. Despite this, a proportion of patients who exhibit positive imaging respond poorly to therapy. Management of NECs is currently limited; evidence for treating NECs with PRRT is scarce.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Butt S, Evans J, Sharma R,

Keywords: neuroendocrine, carcinoma, tumours, PRRT,

#275 The Use of Guar Gum in the Medical Management of Hyperinsulinaemic Hypoglycaemia

Introduction: Medical therapy, including guar gum, is frequently required in the management of patients with endogenous hyperinsulinaemic hypoglycaemia (e.g. insulinoma), especially if surgery is not appropriate.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Carroll R, Todd J,

Keywords: Guar gum, insulinoma, hyperinsulinaemic hypoglycaemia, pregnancy,